Contrast Enhanced Digital Mammography

Global Contrast Enhanced Digital Mammography Market to Reach US$709.5 Million by 2030

The global market for Contrast Enhanced Digital Mammography estimated at US$424.1 Million in the year 2024, is expected to reach US$709.5 Million by 2030, growing at a CAGR of 9.0% over the analysis period 2024-2030. Temporal Subtraction Technique, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$444.6 Million by the end of the analysis period. Growth in the Dual Energy CEDM Technique segment is estimated at 11.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$115.5 Million While China is Forecast to Grow at 12.1% CAGR

The Contrast Enhanced Digital Mammography market in the U.S. is estimated at US$115.5 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$141.5 Million by the year 2030 trailing a CAGR of 12.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.5% and 7.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.0% CAGR.

Global Contrast Enhanced Digital Mammography Market – Key Trends & Drivers Summarized

Why Is Contrast Enhanced Digital Mammography Gaining Prominence in Breast Cancer Diagnostics?

Contrast Enhanced Digital Mammography (CEDM) is increasingly being adopted as a powerful diagnostic tool in breast imaging, offering enhanced sensitivity and specificity in detecting abnormalities, particularly in dense breast tissue. CEDM combines traditional digital mammography with the intravenous injection of iodinated contrast agents, allowing radiologists to visualize areas of increased blood flow—often associated with malignancy—through dual-energy imaging techniques. This approach bridges the diagnostic gap between standard mammography and breast MRI, delivering higher diagnostic accuracy at a fraction of the cost and scan time. With breast cancer being one of the most prevalent cancers among women globally, early and accurate detection is critical for improving patient outcomes and reducing mortality rates. CEDM offers a significant improvement over conventional mammography, particularly in patients with dense breasts, where overlapping tissues can obscure lesions. Its ability to highlight vascularized tumors makes it a valuable adjunct or alternative to MRI, especially in pre-surgical planning, high-risk screenings, and evaluation of treatment response. As awareness around breast cancer screening grows and healthcare systems emphasize early detection, CEDM is gaining traction as a clinically effective and economically viable solution across radiology departments and women’s health centers worldwide.

How Are Clinical Guidelines and Imaging Trends Supporting the Adoption of CEDM?

The expanding use of Contrast Enhanced Digital Mammography is closely linked to evolving clinical guidelines and broader imaging trends that emphasize precision, patient-centered care, and cost-effectiveness. Regulatory bodies and medical associations are increasingly recognizing the diagnostic value of CEDM, particularly in specific use cases such as evaluating inconclusive mammograms, screening high-risk populations, and serving as a viable alternative when MRI is contraindicated. For patients who are claustrophobic, have implanted medical devices, or face insurance barriers, CEDM provides a more accessible and tolerable imaging option. Furthermore, radiologists are integrating CEDM into multimodal diagnostic pathways, using it to complement ultrasound, MRI, and tomosynthesis for a more comprehensive assessment. As imaging centers modernize and expand their diagnostic capabilities, there is a growing push to adopt dual-purpose mammography systems that can perform both standard and contrast-enhanced scans with minimal operational adjustments. This compatibility helps reduce capital investment and training time while enhancing clinical workflow. With increasing emphasis on reducing false positives and avoiding unnecessary biopsies, CEDM’s superior lesion conspicuity and lesion-to-background contrast are becoming vital tools in the radiologist’s arsenal. As a result, healthcare providers are reevaluating their imaging protocols to incorporate CEDM into routine diagnostic and preoperative procedures, accelerating its integration into standard care.

What Technological Advancements Are Enhancing the Performance and Accessibility of CEDM Systems?

Ongoing innovation in imaging technology, contrast agent formulation, and image processing software is significantly elevating the capabilities and accessibility of CEDM systems. Recent advances in dual-energy imaging allow simultaneous acquisition of low- and high-energy images, enabling the subtraction of background breast tissue and enhanced visualization of contrast uptake areas. This dual acquisition approach not only improves diagnostic accuracy but also reduces scan time and minimizes patient discomfort. Newer mammography units are now designed with integrated CEDM capabilities, allowing seamless transition between conventional and contrast-enhanced imaging modes. Software improvements, including AI-powered image interpretation and automated lesion detection, are further aiding radiologists in identifying subtle abnormalities with greater confidence and speed. Innovations in contrast agents are also enhancing safety and image quality, with lower doses and faster clearance profiles reducing the risk of adverse reactions. Additionally, as digital health ecosystems evolve, CEDM systems are being linked with cloud-based PACS (Picture Archiving and Communication Systems), enabling remote consultations and second opinions. Portable and compact systems are being explored for use in outpatient clinics and mobile screening units, broadening access to high-quality breast imaging in underserved or rural regions. Collectively, these technological enhancements are driving operational efficiency, improving diagnostic accuracy, and expanding the global reach of CEDM.

What Are the Main Drivers Propelling the Growth of the Global CEDM Market?

The growth in the contrast enhanced digital mammography market is driven by a combination of clinical, economic, and technological factors aligned with the rising global burden of breast cancer and the need for improved diagnostic tools. A primary growth driver is the increasing incidence of breast cancer, particularly in younger women and in regions with limited access to early detection programs, where CEDM offers a practical and highly effective solution. Healthcare systems are seeking imaging modalities that provide better diagnostic accuracy without incurring the high costs and limited availability associated with MRI, making CEDM an attractive middle ground. The growing emphasis on personalized medicine and risk-based screening protocols is also fueling demand for advanced imaging techniques that can be tailored to individual patient profiles. From a reimbursement standpoint, as insurance policies evolve to cover CEDM procedures, adoption is expected to accelerate further in both public and private healthcare settings. The expansion of breast cancer awareness campaigns, particularly in developing countries, is creating new demand for affordable yet high-resolution diagnostic tools, and CEDM fits this need well. Moreover, hospital investments in next-generation imaging infrastructure and the integration of AI for diagnostic support are enhancing the clinical value and ROI of CEDM installations. These interlinked drivers are positioning contrast enhanced digital mammography as a key component of the future landscape of breast imaging.

SCOPE OF STUDY:

The report analyzes the Contrast Enhanced Digital Mammography market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Technique (Temporal Subtraction, Dual Energy CEDM); Application (Screening, Diagnosis); End-Use (Hospitals, Diagnostic Centers, Specialty Clinics, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• Allengers Medical Systems Ltd.
• Analogic Corporation
• BMI Biomedical International S.R.L.
• Canon Medical Systems Corporation
• Carestream Health
• Fujifilm Holdings Corporation
• GE HealthCare
• Hitachi Medical Systems
• Hologic, Inc.
• iCAD, Inc.
• Konica Minolta, Inc.
• Nanjing Foinoe Co., Ltd.
• Philips Healthcare
• Planmed Oy
• Samsung Medison Co., Ltd.
• Shimadzu Corporation
• Siemens Healthineers AG
• Toshiba Medical Systems Corporation
• Trivitron Healthcare
• Ziehm Imaging GmbH

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.